The FDA today said that the COVID-19 vaccine candidate made by Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) meets success criteria.
Ahead of an advisory meeting on Thursday, Dec. 10, to review the vaccine candidate, the FDA found that data from Pfizer and BioNTech’s trials was “consistent” with its recommendations for emergency use authorization and that the candidate was highly effective without raising any specific safety concerns.
Get the full story at our sister site, MassDevice.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
